The HDAC inhibitor SAHA effectively inhibits tumor cell growth in multiple glioma cell lines and mouse models [79], [80], and a phase 2 clinical trial in patients with recurrent GBM showed modest single-agent activity [81]. The gene discussed is HDAC9; the disease is central nervous system cancer.